Iktos announces a collaboration with Ono for new drug design

pharmafile | March 30, 2022 | News story | Research and Development  

Iktos, a company specialised in AI for new drug design today announced a collaboration agreement with Ono Pharmaceuticals, on innovative medicines dedicated to the fight against disease and pain.

Ono Pharmaceuticals is a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain.

“We are very pleased to collaborate with Ono, a leading pharmaceutical company based in Japan, and proud to announce our first collaboration deal with a Japanese pharma company’’ said Yann Gaston-Mathé, Co-founder and CEO of Iktos. “Our ultimate objective is to expedite drug discovery and achieve time and cost efficiencies for our collaborators by using Iktos’s proprietary AI platform and know-how. We are confident that together we will be able to identify promising novel chemical matter and solve complex multiparametric optimisation problems for Ono’s drug discovery programmes. We are committed to tackle challenging problems alongside our collaborators where we can demonstrate value generation for new and on-going drug discovery projects.”

Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling technologies, and its software, Makya, alongside its AI-based retrosynthesis analysis and planning tool, Spaya. Ono will apply its drug discovery capabilities to expedite the identification of potential pre-clinical candidates, and to identify additional novel chemical matter with suitable properties for Ono’s undisclosed drug discovery programmes.

“Iktos has excellent artificial intelligence technology and platform in drug discovery,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono.  “Through this drug discovery collaboration, we are excited to work with Iktos to identify and develop the next generation of innovative treatments, leading to further expansion of our development pipeline.”

Ana Ovey

Related Content

No items found

Latest content